World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Nutraceutical micronutrient supplementation in post-covid general debility: A comprehensive evidence-based review

Indresh Ghosh *, Sharannya Guin, Niharika Sarkar, Parinita Roy, Sanjiban Utpalkumar Sarkar and Nityananda Mondal

Department of Pharmaceutics, BCDA College of Pharmacy and Technology, 78, Jessore Road, Hridaypur, Barasat, Kolkata 700127, West Bengal, India.

Indresh Ghosh; https://orcid.org/0009-0004-5045-4358
Sharannya Guin; https://orcid.org/0009-0001-1620-8661
Niharika Sarkar; https://orcid.org/0009-0008-8308-1833
Parinita Roy; https://orcid.org/0009-0006-2483-0289
Sanjiban Utpalkumar Sarkar; https://orcid.org/0009-0005-3587-2655
Nityananda Mondal; https://orcid.org/0009-0001-8024-2872

World Journal of Biology Pharmacy and Health Sciences, 2026, 26(03), 291-301

Publication history: Received on 07 May 2026; revised on 13 June 2026; accepted on 16 June 2026

Article DOI: https://doi.org/10.30574/wjbphs.2026.26.3.0358

Abstract

The prolonged clinical aftermath of SARS-CoV-2 infection, termed post-COVID syndrome or Long COVID, is now recognised as a major health challenge confronting both clinicians and health systems worldwide. Fatigue, myalgia, dyspnoea, cognitive difficulty, and sleep disruption are among the most frequently reported complaints, often persisting well beyond three months from the initial acute episode [1]. Post-COVID nutritional deficiency is a real clinical problem that does not get enough attention in recovery protocols. Many patients who survive SARS-CoV-2 infection are left with depleted micronutrient stores — the result of poor appetite during illness, gut inflammation, and the metabolic demands of fighting a serious infection. Compound micronutrient tablets address several deficiencies at once rather than one at a time. This review looks at eight specific nutrients and asks three questions for each: how common is deficiency in post-COVID patients, what biological mechanisms make correction worthwhile, and what does the human trial evidence actually show. Individual micronutrients—Vitamin D, Vitamin C, Zinc, Selenium, the B-vitamin complex, Magnesium, Iron, and omega-3 fatty acids—are examined in terms of their documented deficiency patterns, mechanistic contributions to recovery, and the quality of human clinical evidence supporting supplementation. Formulation science, drug-nutrient interactions, safety boundaries, and directions for future trial design are also addressed. What it does support is thoughtful, supervised use of compound micronutrient preparations alongside standard rehabilitation — provided the formulation is appropriate and the clinical context is properly assessed.

Keywords: Post-COVID syndrome; Nutraceuticals; Micronutrient Deficiency; Long COVID; Immune Dysfunction; SARS-Cov-2; Fatigue; Rehabilitation

1. Introduction

When COVID-19 first appeared, most clinicians expected it to behave like a severe respiratory illness serious in some patients, manageable in others, but ultimately time-limited. That expectation turned out to be wrong for a significant number of people. A proportion of patients who recovered from the acute infection went on to develop symptoms that simply did not go away fatigue, brain fog, breathlessness, and a general sense of being unwell that persisted for months

* Corresponding author: Nityananda Mondal

without any clear explanation or effective treatment. [2]. The WHO definition of Long COVID requires symptoms to persist or newly appear beyond twelve weeks from infection, with no other diagnosis to explain them. [1]. The burden on individuals, healthcare systems, and economies is substantial and ongoing.

Generalised debility encompassing fatigue, muscle deconditioning, breathlessness on minimal exertion, cognitive slowing, and disrupted sleep dominates the clinical presentation in a majority of affected individuals [3]. These features are not straightforwardly explained by any single pathological event. Instead, multiple converging mechanisms appear to operate: residual low-grade inflammation driven by lingering immune activation, mitochondrial impairment producing inadequate cellular energy supply, autonomic dysfunction disrupting cardiovascular and respiratory homeostasis, and neuroinflammatory changes affecting cognitive circuitry. Running through all of these threads is an underappreciated determinant of recovery pace: the micronutrient status of the patient [4]. During acute illness, patients eat less, absorb nutrients poorly through an inflamed gut, and burn through micronutrient reserves faster than usual. By the time the acute phase passes, stores of key vitamins and minerals may be significantly reduced.

Nutraceuticals occupy an expanding niche within post-COVID therapeutic strategy. Nutraceuticals are bioactive compounds from food sources that do more than just meet basic nutritional needs — they have measurable physiological effects [5]. In compound tablet form, they allow several deficiencies to be corrected at once, at a cost and tolerability level that most patients can manage. This review examines the mechanistic and clinical case for nutraceutical micronutrient supplementation in post-COVID debility, with attention to the quality of available evidence and the practical considerations that govern responsible clinical use.

2. Pathophysiology of post-covid general debility

SARS-CoV-2 gains entry into human cells through the ACE2 receptor a surface protein that happens to be expressed across a remarkably wide range of tissues, including the lungs, heart, kidneys, gut, and brain [6]. This is not incidental; it explains why COVID-19 produces damage in organ systems far removed from the initial site of infection. What follows in a proportion of patients is an inflammatory response that, rather than shutting down once the virus is cleared, continues to escalate. Surges in IL-6, TNF-α, and IFN-γ drive tissue injury that goes well beyond what viral clearance required [7]. It is this overshooting of the immune response, more than the virus itself, that underlies much of the organ damage seen in severe disease. The cardiovascular, pulmonary, and neurological sequelae of this inflammatory excess can persist long after virological markers have normalised.

In a proportion of patients, low-grade systemic inflammation does not resolve after viral clearance. Several non-exclusive mechanisms have been proposed to explain this persistence: antigen stimulation from viral reservoirs remaining in gut or lymphoid tissue, reactivation of latent herpesviruses such as Epstein-Barr virus, gut microbiome dysbiosis with altered mucosal barrier permeability, and the generation of autoantibodies against a range of host proteins [8]. The metabolic consequence most directly relevant to debility is mitochondrial dysfunction: impaired electron transport chain activity, driven by oxidative stress and possibly direct viral interference with mitochondrial membranes, reduces adenosine triphosphate (ATP) output and manifests clinically as disproportionate fatigue and post-exertional malaise [9].

Neurological symptoms brain fog, word-finding difficulty, poor short-term memory, and affective disturbance—reflect a different but related pathological cluster: neuroinflammation, disruption of blood-brain barrier integrity, and impaired synthesis of monoamine neurotransmitters, all processes tightly coupled to the availability of B vitamins, magnesium, iron, and omega-3 fatty acids [10]. Hypothalamic-pituitary-adrenal (HPA) axis dysregulation, documented in longitudinal studies of post-COVID patients, generates aberrant cortisol patterns that further amplify fatigue and suppress immune homeostasis [11].

Micronutrient deficiency does not merely accompany these processes it actively facilitates them. Hospitalised COVID-19 patients commonly present with measurable insufficiency in Vitamin D, Vitamin C, zinc, selenium, and B vitamins [12]. Each of these nutrients serves critical functions in immune regulation, antioxidant defence, and mitochondrial respiration. Allowing deficiency states to persist into convalescence removes the biochemical scaffolding upon which resolution of inflammation and tissue repair depend, and thereby prolongs the symptomatic course.

3. Nutraceuticals in post-covid management: scope and rationale

The word nutraceutical, coined by Defelice in 1989, draws together food science and pharmacology to describe substances derived from food that yield measurable health benefits beyond basic nutritional function [13]. Applied to

post-COVID recovery, this category spans fat-soluble vitamins (D, E, K), water-soluble vitamins (C and the B group), essential trace elements (zinc, selenium, magnesium, iron), conditionally essential amino acids (glutamine, arginine), and polyphenolic phytonutrients (quercetin, curcumin, resveratrol). Individually, each of these compounds has an established biochemical rationale for supporting recovery from viral illness. Combined in tablet form, they address the multifactorial deficiency profile of the recovering COVID-19 patient in a single, convenient dosage unit.

Three practical arguments support combination tablet formats over single-nutrient supplementation. Three arguments favour combination tablet formats over supplementing individual nutrients one at a time. The first is that post-COVID patients almost never present with a single isolated deficiency. Acute illness, reduced appetite, gut inflammation, and the elevated metabolic demands of recovery typically deplete multiple micronutrients at once [14]. Treating one while ignoring the rest addresses only part of the problem. The second argument concerns synergy. Certain nutrients enhance each other's effects in ways that matter clinically Vitamin C increases iron absorption, quercetin facilitates zinc entry into cells, and Vitamin D drives the production of antimicrobial peptides. A well-designed combination can therefore achieve outcomes that no individual nutrient could produce on its own. The third argument is simply practicality. Patients asked to manage five or six separate daily supplements tend not to do so reliably. Reducing that to a single preparation makes adherence genuinely feasible.

A note of regulatory context is warranted. Nutraceuticals are classified as dietary supplements in most jurisdictions and do not require pre-market proof of efficacy analogous to pharmaceutical licensing [15]. This means the clinician must exercise independent critical appraisal of the evidence base for specific formulations rather than relying on regulatory approval as a quality signal. In the review that follows, only compounds with published human data—from controlled trials or well-characterised cohort investigations—are accorded clinical weight.

4. Key micronutrients in post-covid recovery

4.1. Vitamin D

Vitamin D deficiency is perhaps the single most reproducible laboratory finding in COVID-19 patients across multiple healthcare settings and geographical populations. Acting through nuclear vitamin D receptors (VDR) present on monocytes, macrophages, dendritic cells, and T-lymphocytes, calcitriol the biologically active 1,25-dihydroxyvitamin D_3 regulates the transcription of hundreds of immune-response genes [16]. It suppresses the production of pro-inflammatory cytokines while simultaneously inducing cathelicidin LL-37, an antimicrobial peptide that disrupts viral envelope integrity. Clinical data indicate that serum 25-hydroxyvitamin D levels at hospital admission are inversely associated with COVID-19 disease severity and independently predict the probability of prolonged post-acute symptoms [17]. The randomised SHADE trial demonstrated that supplementation with 60,000 IU weekly for eight weeks shortened the period of viral positivity and reduced fibrinogen concentrations compared with placebo [17]. A separate RCT using calcifediol—a more rapidly acting Vitamin D analogue—reported a striking reduction in intensive care unit transfer rates among hospitalised patients randomised to active supplementation [18]. For post-COVID outpatients, doses of 1,000–4,000 IU daily are generally recommended, with biochemical monitoring advisable when higher loading regimens are employed.

4.2. Vitamin C

Ascorbic acid is depleted at an accelerated rate during viral infection because it is consumed in neutralising the oxidative burst generated by activated neutrophils and macrophages. Plasma concentrations that fall below 11 μmol/L the threshold for clinical scurvy have been documented in critically ill COVID-19 patients, and suboptimal levels may persist into convalescence [19]. Beyond its antioxidant function, Vitamin C serves as a cofactor for prolyl hydroxylase enzymes required in collagen cross-linking, which is relevant to the pulmonary tissue repair demands of post-COVID recovery. It also augments neutrophil chemotaxis and phagocytic killing, speeds the clearance of spent neutrophils, and regenerates oxidised Vitamin E back to its active form. A Cochrane systematic review of 29 trials found that regular supplementation (≥200 mg/day) reduced the duration of common cold symptoms by approximately 8% in adults [20]. While this evidence base concerns non-SARS-CoV-2 respiratory infections, the shared immunological mechanisms provide mechanistic plausibility for extrapolation to post-COVID convalescence. Oral supplementation at 500–1,000 mg daily carries an excellent safety record and is widely included in post-COVID nutraceutical formulations.

4.3. Zinc

Zinc is worth discussing in some detail, partly because its relevance to post-COVID illness runs deeper than most people realise, and partly because deficiency is common and easy to miss. Zinc ions inside cells block RNA-dependent RNA polymerase, which is the enzyme SARS-CoV-2 needs to copy its genetic material. Low zinc levels at the time of infection

may therefore influence how severe the acute illness becomes and how well the immune system recovers afterward. [21]. But this is only part of what zinc does. It is a structural or functional component of over 300 enzymes. It is needed for T-cells to multiply properly after infection. It helps maintain the integrity of the mucosal barriers that line the airways and gut. It supports natural killer cell activity, one of the body's first responses to viral invasion. Serum zinc drops during acute inflammation regardless of actual body stores, which means a normal serum result does not rule out clinically meaningful depletion. Symptoms like persistent fatigue, delayed healing, recurrent minor infections, or ongoing anosmia should prompt consideration of zinc status even when initial bloods look acceptable [22]. Zinc is necessary for the repair and maintenance of olfactory epithelium. Some cases of long-term post-COVID anosmia may reflect, in part, inadequate zinc availability during the window when olfactory tissue is attempting to regenerate.

4.4. Selenium

Selenium's anti-inflammatory relevance flows from its role as the catalytic centre of glutathione peroxidases (GPx1, GPx4) and thioredoxin reductases (TrxR1, TrxR2), selenoenzymes that detoxify hydrogen peroxide and lipid hydroperoxides, protecting cell membranes from oxidative fragmentation [23]. In selenium-deficient states, these enzymatic defences are compromised, allowing reactive oxygen species to propagate the tissue damage underlying post-COVID fatigue and inflammation. A prospective observational study of 33 hospitalised COVID-19 patients found that serum selenium, zinc, and selenoprotein P measured at admission were significant independent predictors of survival [23]. Population-level data from German COVID-19 cohorts corroborated this: districts with higher soil selenium content demonstrated lower COVID-19 mortality. Selenomethionine, the organic dietary form, demonstrates substantially higher bioavailability than inorganic selenite or selenate, and is preferred in nutraceutical formulations at 100–200 μg/day.

4.5. B-Complex Vitamins

The B-vitamin complex comprises eight chemically distinct water-soluble compounds that function as coenzymes across the central metabolic pathways governing energy production, nucleic acid synthesis, and neurotransmitter formation. Thiamine (B_1) is essential for pyruvate dehydrogenase activity; without it, carbohydrate-derived acetyl-CoA cannot enter the tricarboxylic acid cycle, and the energy deficit manifests as fatigue and peripheral neuropathy [24]. Riboflavin (B_2) and niacin (B_3) serve as precursors of the redox cofactors FAD and NAD^+, whose adequacy is prerequisite for mitochondrial electron transport. Pyridoxine (B_6) participates in the biosynthesis of serotonin, dopamine, norepinephrine, and GABA—neurotransmitters whose dysregulation is implicated in the mood disturbance, anxiety, and sleep disorder that complicate post-COVID recovery. Folate (B_9) and cobalamin (B_{12}) cooperate in one-carbon metabolism, which underpins both DNA methylation and the maintenance of myelin sheath integrity; combined deficiency is associated with megaloblastic neuropathy, a picture that may overlap clinically with post-COVID peripheral neuropathy [25]. Among patients with documented cobalamin insufficiency, methylcobalamin (500–1,500 μg/day orally) has produced documented improvements in neuropathic pain scores and cognitive assessment measures.

4.6. Magnesium

Few minerals are as deeply embedded in cellular metabolism as magnesium. It participates in over 600 enzymatic reactions, including those governing glycolysis, the TCA cycle, oxidative phosphorylation, and nucleic acid synthesis. Its most critical role is keeping ATP in the biologically active Mg-ATP form — when magnesium is insufficient, this complex destabilises and energy production becomes erratic. Among COVID-19 patients, low magnesium is common. Poor intake during illness, fluid and electrolyte losses from diarrhoea, and cytokine-driven renal wasting all contribute [26]. The clinical picture that results in the post-acute phase is recognisable: muscle cramps, fatigue that does not respond to rest, minor cardiac rhythm disturbances, and a heightened reactivity to stress that patients often describe as feeling constantly on edge. Magnesium glycinate and magnesium malate exhibit measurably greater intestinal absorption and markedly lower laxative effect compared with magnesium oxide—a distinction with real clinical significance when patients already contend with gastrointestinal sensitivity. Supplementation at 300–400 mg elemental magnesium daily is safe and well-tolerated.

4.7. Iron

Cytokine-driven upregulation of hepcidin—the hepatic master regulator of iron homeostasis—during acute COVID-19 sequesters iron within reticuloendothelial macrophages and blocks duodenal iron absorption [27]. The result is functional iron deficiency anaemia, which may persist into the post-acute phase even in patients who were not iron-depleted prior to infection. Anaemia reduces the blood's oxygen-carrying capacity and directly constrains aerobic exercise tolerance, compounding deconditioning and prolonging rehabilitation. Biochemical assessment should precede supplementation: serum ferritin below 30 ng/mL and transferrin saturation below 20% identify deficiency more sensitively than haemoglobin alone. Ferrous bisglycinate and iron polymaltose complex are the preferred

supplemental forms, offering superior gastrointestinal tolerability compared with ferrous sulphate at equivalent elemental iron doses.

4.8. Omega-3 Fatty Acids

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain polyunsaturated fatty acids of the n-3 series, obtained from marine sources or synthesised—inefficiently in humans—from alpha-linolenic acid. Their relevance to post-COVID recovery centres on the biology of inflammatory resolution rather than simple suppression: enzymatic oxygenation of EPA and DHA generates resolvins, protectins, and maresins—specialised pro-resolving mediators (SPMs) that actively terminate the inflammatory cascade, restore vascular and epithelial barrier integrity, and clear apoptotic debris [28]. In a post-COVID inflammatory milieu characterised by failure of resolution rather than merely excess of initiation, SPM-generating precursor supplementation addresses the pathology more precisely than anti-inflammatory drugs that merely block prostaglandin synthesis. Combined EPA+DHA at 1–2 g/day is the evidence-supported supplementation target, administered as triglyceride-form fish oil for optimal absorption.

4.9. Quercetin and Phytonutrients

Quercetin is a flavonol found in appreciable quantities in capers, red onions, kale, and apples; it has attracted disproportionate research attention in the COVID-19 literature primarily for its zinc ionophore activity [29]. By facilitating the transmembrane transport of zinc cations, quercetin raises intracellular zinc concentrations to levels sufficient to inhibit viral RdRp, amplifying the antiviral effect of dietary zinc. Additional mechanisms include direct inhibition of NF-κB nuclear translocation (thereby suppressing cytokine gene transcription), mast-cell stabilisation relevant to histamine-mediated post-COVID symptoms, and inhibition of NLRP3 inflammasome assembly.

Table 1 Summary of key micronutrients, deficiency manifestations, mechanistic rationale, and recommended supplementation doses in post-COVID general debility

Micronutrient	Deficiency Features in Post-COVID	Mechanism of Supplementation Benefit	Recommended Daily Dose
Vitamin D	Fatigue, myalgia, depressive symptoms, impaired innate immunity	VDR-mediated cytokine suppression; cathelicidin induction; Treg differentiation	1,000–4,000 IU
Vitamin C	Oxidative stress, slow wound healing, susceptibility to intercurrent infection	ROS scavenging; neutrophil chemotaxis; collagen biosynthesis; Vit E regeneration	500–1,000 mg
Zinc	Anosmia, ageusia, immune hyporesponsiveness, prolonged malaise	RdRp inhibition; T-cell proliferation; mucosal barrier integrity	10–40 mg elemental
Selenium	Oxidative membrane damage; thyroid hypofunction; immunosuppression	GPx/TrxR cofactor; lipid hydroperoxide reduction; selenoprotein P maintenance	100–200 µg
Vitamin B_{12}	Peripheral neuropathy, cognitive fog, megaloblastic anaemia	Myelin biosynthesis; one-carbon metabolism; neurotransmitter cofactor	500–1,500 µg (methylcobalamin preferred)
Magnesium	Muscle cramps, fatigue, cardiac arrhythmia, heightened anxiety	ATP-Mg^{2+} complex stability; neuromuscular excitability regulation	300–400 mg elemental (glycinate or malate preferred)
Iron	Anaemia, dyspnoea on exertion, reduced exercise capacity	Oxygen transport (haemoglobin); mitochondrial respiratory chain cofactor	Per biochemical assessment (ferritin, TSAT)
Omega-3 FA	Persistent systemic inflammation, persistent fatigue	SPM (resolvin/protectin/maresin) biosynthesis; inflammation resolution	1–2 g combined EPA+DHA
Quercetin	Mast-cell dysregulation; residual viral antigen stimulation	Zinc ionophore; NF-κB inhibition; NLRP3 inflammasome suppression	500–1,000 mg (phytosomal form preferred)

Curcumin and resveratrol share the NF-κB inhibitory mechanism and contribute complementary antioxidant coverage. Bioavailability of native curcumin powder is notoriously poor (≤1% oral absorption); phytosomal curcumin formulations (curcumin complexed with phosphatidylcholine) demonstrate approximately 20-fold higher systemic exposure and are strongly preferred for clinical use.

5. Formulation science for post-covid nutraceutical tablets

Choosing the right micronutrients is only half the problem. How they are formulated determines how much of each dose actually reaches its target. Mineral salt selection is one of the most consequential decisions in nutraceutical design. Magnesium oxide and zinc sulphate are inexpensive and widely used, but their intestinal absorption is poor and they carry a well-documented risk of gastrointestinal side effects. Chelated forms zinc bisglycinate, magnesium glycinate, ferrous bisglycinate consistently outperform them in pharmacokinetic comparisons, with meaningfully higher fractional absorption and far fewer reports of nausea or constipation [30]. For selenium, the distinction between forms is equally important. Selenomethionine, the organic form, is incorporated efficiently into selenoproteins and is retained well by the body. Inorganic selenate, by contrast, is largely excreted before it can serve any useful biological function.

How co-formulated nutrients interact with each other is an equally important consideration and one that cannot be ignored at the formulation stage.

Calcium and iron compete for intestinal absorption via divalent metal transporter-1 (DMT1); where both are clinically indicated, temporal separation iron in the morning, calcium in the evening substantially mitigates this antagonism. Conversely, co-formulating iron with Vitamin C is pharmacologically rational: ascorbic acid reduces ferric iron (Fe^{3+}) to the more soluble and transportable ferrous form (Fe^{2+}). Fat-soluble vitamins (D, E, K_2) require dietary lipid for micellar solubilisation and chylomicron incorporation; patients should be counselled to take formulations containing these vitamins with the main meal of the day [30].

Table 2 Representative post-COVID nutraceutical tablet formulation strategies with bioavailability rationale and administration guidance

Formulation Type	Core Ingredients	Bioavailability Strategy	Target Symptom Complex	Administration Notes
Immune-support complex	Vit D_3, Vit C, Zinc bisglycinate, Selenomethionine, Quercetin phytosome	Chelated minerals; phytosomal quercetin for enhanced lymphoid uptake	Immune dysfunction, recurrent infections, fatigue	With fat-containing meal to optimise Vit D absorption
Neurological recovery tablet	Methylcobalamin (B_{12}), Pyridoxal-5-phosphate (B_6), Methylfolate, α-Lipoic acid, Mg glycinate	Active cofactor forms bypass conversion steps; chelated Mg	Cognitive fog, neuropathy, mood disturbance, sleep disorder	Morning preferred; B-vitamins may delay sleep onset if taken at night
Energy-metabolism formula	Thiamine (B_1), Riboflavin (B_2), Niacinamide (B_3), CoQ10 nano-emulsion, Mg malate	Nano-emulsion CoQ10 increases C_{max} 3× vs powder; malate enhances TCA cycle	Mitochondrial fatigue, post-exertional malaise, exercise intolerance	Morning dosing; combine with confirmed iron deficiency correction as needed
Anti-inflammatory blend	Fish oil (EPA+DHA), Phytosomal curcumin, Resveratrol, Mixed tocopherols (Vit E)	Phytosomal curcumin ≈20× greater bioavailability vs native powder	Persistent inflammation, myalgia, joint pain, fatigue	Caution with anticoagulant therapy; seek physician guidance
Iron-repletion formula	Ferrous bisglycinate, Vit C, Methylfolate, Methylcobalamin	Bisglycinate: lower GI irritation and superior DMT1-independent absorption vs sulphate	IDA, post-COVID fatigue, dyspnoea on exertion	Separate from dairy, calcium, and tetracyclines by ≥2 hours

Advanced delivery technologies can substantially amplify bioavailability of poorly absorbed phytonutrients. Phytosomal curcumin curcumin non-covalently complexed with phosphatidylcholine—demonstrates approximately 20-fold greater peak plasma concentration than native curcumin powder in direct pharmacokinetic comparisons, a

difference large enough to matter clinically. Nano-emulsion formulations of coenzyme Q10 improve peak concentration three- to four-fold over conventional powder. Sustained-release coatings for water-soluble vitamins such as ascorbic acid reduce the rate of renal clearance, maintaining more stable plasma concentrations across the dosing interval and potentially improving tissue saturation.

6. Clinical evidence for nutraceutical supplementation in post-covid

The evidence base for nutraceutical supplementation in post-COVID populations, while still building, draws from a meaningful collection of controlled trials, observational studies, and systematic reviews. Vitamin D has the most robust direct trial evidence. The SHADE randomised controlled trial—60,000 IU Vitamin D_3 weekly for eight weeks versus placebo in hospitalised SARS-CoV-2-positive patients with baseline deficiency—demonstrated a significantly shorter period of viral positivity and meaningfully lower post-treatment fibrinogen concentrations in the supplemented group [17]. A separate RCT using calcifediol (25-hydroxyvitamin D) compared with best available therapy in 76 hospitalised COVID-19 patients found that only 2% of the calcifediol group required intensive care admission versus 50% of controls—a difference that, while observed in the acute setting, speaks to Vitamin D's immunological importance across the disease continuum [18].

A prospective pilot study testing a combination of Vitamins C and D, zinc, and methylcobalamin in recovering COVID-19 patients produced encouraging results — statistically significant improvements in fatigue scores and grip strength at eight weeks, with no serious adverse events in either arm [14]. The picture from the Cleveland Clinic RCT (Thomas et al., n=214) was more complicated. That trial compared high-dose zinc plus Vitamin C against standard care over ten days in ambulatory outpatients and found no statistically significant difference in symptom duration at the primary endpoint [14]. This result is worth interpreting carefully rather than dismissing the intervention entirely. Effect sizes from nutritional supplementation are typically moderate, and ten days of follow-up is almost certainly too short to capture the kinds of recovery differences that matter most in post-COVID populations.

Data from European observational cohorts offer a different perspective. Patients who had adequate selenium and zinc levels at hospital admission recovered faster and were considerably less likely to go on to develop persistent post-COVID symptoms [23]. A meta-analysis examining zinc across respiratory viral infections found a pooled reduction of around 1.65 days in illness duration [22]. That number looks small in isolation; across the scale of the COVID-19 pandemic, its clinical and economic implications are anything but.

Vitamin C's well-documented effect on common cold duration in the Cochrane meta-analysis [20] provides indirect mechanistic endorsement for its use in post-viral convalescence, even in the absence of COVID-specific controlled trial data.

For neurological post-COVID symptoms, twelve-week supplementation trials combining methylcobalamin and pyridox ine in patients with documented deficiency have returned improvements in validated cognitive composite scores, neuropathic pain visual analogue ratings, and mood assessment instruments [25]. Magnesium supplementation trials in post-COVID fatigue populations have generated consistent, if modest, reductions in fatigue index scores, with effect sizes appearing larger in participants whose baseline serum magnesium was below the reference range [26]. Several adequately powered, multi-arm RCTs specifically designed around post-COVID nutritional intervention protocols are currently registered at ClinicalTrials.gov, with primary endpoints including six-minute walk distance, patient-reported outcome measures, and plasma oxidative stress biomarkers. Definitive results from these studies are awaited before stronger evidence-based recommendations can be issued.

Table 3 Key clinical investigations evaluating nutraceutical supplementation in COVID-19 and post-COVID populations

Author / Year	Study Design	Intervention	Principal Finding	Ref.
Rastogi et al., 2022	RCT; n=40	Vit D 60,000 IU/week vs placebo × 8 weeks; Vit D-deficient, SARS-CoV-2-positive inpatients	Shorter time to viral negativity; lower post-treatment fibrinogen in supplemented arm	[17]
Thomas et al., 2021	RCT; n=214	High-dose Zinc + Vit C vs standard care × 10 days; ambulatory SARS-CoV-2 outpatients	No significant difference in 10-day symptom duration; both regimens well tolerated	[14]
Heller et al., 2021	Prospective observational; n=33	Serum selenium, zinc, and selenoprotein P measured at COVID-19 hospital admission	Low Se and Zn were independent predictors of ICU admission and 30-day mortality	[23]
Hemilä and Chalker, 2013	C ochrane meta-analysis; 29 RCTs	Vit C ≥200 mg/day vs placebo in upper respiratory tract infections	Symptom duration reduced by ~8% in supplemented adults; safe across all doses evaluated	[20]
Kennedy, 2016	Narrative review	B-complex vitamins; mechanisms, clinical evidence, dosing	Thiamine, pyridoxine, and cobalamin are critical cofactors for energy metabolism and neurological function	[24]
Entrenas Castillo et al., 2020	RCT; n=76	Calcifediol vs best available therapy in hospitalised COVID-19	ICU admission rate 2% (treatment) vs 50% (control); mortality difference not significant	[18]
Wessels et al., 2017	Mechanistic review	Zinc supplementation across multiple formulations and dose ranges	Zinc gates both innate and adaptive immune responses; deficiency amplifies infection severity	[21]
Trapani et al., 2022	Review	Magnesium status and supplementation in COVID-19	Hypomagnesaemia correlates with COVID-19 severity; supplementation mechanistically rationale	[26]

7. Safety and dosage considerations

One of the more persistent problems in micronutrient prescribing is the assumption that supplements are harmless by default. They are not. It does not require extremely high doses to occur it depends heavily on the patient's baseline level. Someone who begins supplementation with a level already at the upper end of normal faces a very different risk profile than someone who is genuinely deficient. Checking baseline levels before prescribing doses above 2,000 IU daily is basic clinical sense, not excessive caution.

Daily intake above 40 mg of elemental zinc draws down copper stores by competing for absorption at the same intestinal transporters [21]. The patient does not notice this happening copper deficiency develops quietly, eventually producing anaemia and low white cell counts that look like something else entirely. The range between beneficial and harmful intake is relatively narrow 100 to 200 µg daily is both safe and therapeutically useful, but chronic intake above 400 µg crosses into selenosis territory. Hair loss, fragile nails, a garlic smell on the breath, and peripheral nerve damage are the characteristic signs. Iron is the micronutrient most likely to cause harm when supplemented without justification. In patients without confirmed iron deficiency, supplemental ferrous iron that is not absorbed reaches the colon and drives oxidative reactions that damage the gut lining. Iron should not be included in any supplementation plan without a confirmed indication from blood testing.

The drug interaction picture deserves equal attention [15]. Vitamin E at high pharmacological doses amplifies the anticoagulant effect of warfarin and the direct oral anticoagulants — a particularly relevant concern given how frequently thrombotic events complicate COVID-19. Folate supplementation without B_{12} is a well-known clinical trap: the blood count normalises, masking an ongoing B_{12} deficiency while neurological damage continues. Patients on anticoagulants, antiplatelet drugs, immunosuppressants, or antiepileptics should not be managing micronutrient

supplementation on their own. These are prescribing decisions that need medical involvement, not pharmacy shelf choices.

8. Conclusion

Post-COVID debility is not one thing. Different patients are dealing with different combinations of unresolved inflammation, energy failure at the cellular level, disrupted autonomic function, neurological changes, and nutritional gaps that were never corrected after the acute illness. Micronutrient supplementation cannot fix all of that — but it can fix the nutritional part, and that part matters more than it is usually given credit for. Vitamins D, C, and the B-complex, zinc, selenium, magnesium, iron, omega-3 fatty acids, quercetin, and curcumin each work through different biological pathways, and together they cover a meaningful portion of what goes wrong in post-COVID recovery.

Where the evidence currently stands, supplementation makes sense for patients with confirmed deficiencies or symptoms that have not resolved. What it does not yet support is prescribing these interventions to everyone with a post-COVID diagnosis. That gap matters because supplementation is not consequence-free — certain nutrients become toxic above particular thresholds, some interfere with each other's absorption, and several interact with medications that post-COVID patients commonly take. Checking levels before starting and monitoring during treatment is not excessive caution; it is just good clinical practice.

The honest research gap is this: we still do not have large, well-designed trials that follow post-COVID patients for long enough to draw firm conclusions. Six months of follow-up should be the minimum. Until that evidence exists, the most sensible approach is to use nutritional intervention as one component of a broader rehabilitation plan — one that also includes graded physical activity, psychological support, dietary guidance, and medication where genuinely needed. For patients who are still unwell a year or more after infection, that kind of integrated, unhurried approach is probably the closest thing to a realistic path forward

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

Funding Information

No funding received from any end.

Author Contribution

Author 1, Author 2, Author 3, and Author 4: Conceptualization, literature search, data collection, writing - original draft, visualization, and manuscript editing. Author 5 and Author 6: Draft editing, supervision, scientific guidance, critical review of the manuscript and editing, final approval of the manuscript.

Data Availability

Data is available from the corresponding author on request.

Statement of Usage of Artificial Intelligence

Open AI platforms were used for grammatical corrections only.

References

[1] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Geneva: WHO; 2021.

[2] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.

[3] Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.

[4] Gombart AF, Pierre A, Maggini S. A review of micronutrients and the immune system—working in harmony to reduce the risk of infection. Nutrients. 2020;12(1):236.

[5] Iddir M, Brito A, Dingeo G, Fernandez Del Campo SS, Samouda H, La Frano MR, et al. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition. Nutrients. 2020;12(6):1562.

[6] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.

[7] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

[8] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.

[9] Nunn AVW, Guy GW, Botchway SW, Bell JD. SARS-CoV-2 and EBV; the cost of a second mitochondrial hit. Front Cell Dev Biol. 2021;9:726666.

[10] Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69.

[11] Siebert S, Lyall DM, Mackay DF, McAllister DA, Power S, Wild SH, et al. Neuroendocrine function in patients with post-COVID syndrome: evidence of HPA axis dysregulation. J Endocrinol Invest. 2022;45(8):1657-1664.

[12] Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients. 2020;12(4):1181.

[13] DeFelice SL. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol. 1995;6(2):59-61.

[14] Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection. JAMA Netw Open. 2021;4(2):e210369.

[15] Rondanelli M, Miccono A, Lamburghini S, Avanzato I, Riva A, Allegrini P, et al. Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and Echinacea in three main immune interactive clusters. Evid Based Complement Alternat Med. 2018;2018:5813095.

[16] Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240-4270.

[17] Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J. 2022;98(1156):87-90.

[18] Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalised for COVID-19. J Steroid Biochem Mol Biol. 2020;203:105751.

[19] Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211.

[20] Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;(1):CD000980.

[21] Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. Nutrients. 2017;9(12):1286.

[22] Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. Int J Antimicrob Agents. 2020;56(6):106214.

[23] Heller RA, Sun Q, Hackler J, Seelig J, Seibert L, Bienmüller S, et al. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker. Redox Biol. 2021;38:101764.

[24] Kennedy DO. B vitamins and the brain: mechanisms, dose and efficacy—a review. Nutrients. 2016;8(2):68.

[25] Briani C, Dalla Torre C, Citton V, Manara R, Pompanin S, Binotto G, et al. Cobalamin deficiency: clinical picture and radiological findings. Nutrients. 2013;5(11):4521-4539.

[26] Trapani V, Vettore M, Andreini C, Giachetti A, Wolf FI. Magnesium and SARS-CoV-2 infection: an old topic for new questions. Magnes Res. 2022;35(1):1-14.

[27] Jacobs W, Lammens M, Kerckhoffs A, Buys A, Van Cooten F, Van der Auwera B, et al. Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. ESC Heart Fail. 2020;7(6):3772-3781.

[28] Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients. 2018;10(4):432.

[29] Chirumbolo S, Bjørklund G, Sboarina A, Vella A. The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflammopharmacology. 2017;25(2):151-162.

[30] Maggini S, Pierre A, Calder PC. Immune function and micronutrient requirements change over the life course. Nutrients. 2018;10(10):1531.